Literature DB >> 29052160

The Use of Mapping to Estimate Health State Utility Values.

Roberta Ara1, Donna Rowen2, Clara Mukuria1.   

Abstract

Mapping functions are estimated using regression analyses and are frequently used to predict health state utility values (HSUVs) in decision analytic models. Mapping functions are used when evidence on the required preference-based measure (PBM) is not available, or where modelled values are required for a decision analytic model, for example to control for important sociodemographic variables (such as age or gender). This article provides an overview of the latest recommendations including pre-mapping considerations, the mapping process including data requirements for undertaking the estimation of mapping functions, regression models for estimating mapping functions, assessing performance and reporting standards for mapping studies. Examples in rheumatoid arthritis are used for illustration. When reporting the results of mapping standards the following should be reported: a description of the dataset used (including distributions of variables used) and any analysis used to inform the selection of the model type and model specification. The regression method and specification should be justified, and as summary statistics may mask systematic bias in errors, plots comparing observed and predicted HSUVs. The final model (coefficients, error term(s), variance and covariance) should be reported together with a worked example. It is important to ensure that good practice is followed as any mapping functions will only be as appropriate and accurate as the method used to obtain them; for example, mapping should not be used if there is no overlap between the explanatory and target variables.

Entities:  

Mesh:

Year:  2017        PMID: 29052160     DOI: 10.1007/s40273-017-0548-7

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  16 in total

1.  Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values.

Authors:  Mónica Hernández Alava; Allan J Wailoo; Roberta Ara
Journal:  Value Health       Date:  2012-03-23       Impact factor: 5.725

Review 2.  A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures.

Authors:  John E Brazier; Yaling Yang; Aki Tsuchiya; Donna Louise Rowen
Journal:  Eur J Health Econ       Date:  2009-07-08

3.  Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

Authors:  N P Hurst; P Kind; D Ruta; M Hunter; A Stubbings
Journal:  Br J Rheumatol       Date:  1997-05

4.  Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report.

Authors:  Allan J Wailoo; Monica Hernandez-Alava; Andrea Manca; Aurelio Mejia; Joshua Ray; Bruce Crawford; Marc Botteman; Jan Busschbach
Journal:  Value Health       Date:  2017-01       Impact factor: 5.725

5.  Mapping to obtain EQ-5D utility values for use in NICE health technology assessments.

Authors:  Louise Longworth; Donna Rowen
Journal:  Value Health       Date:  2013 Jan-Feb       Impact factor: 5.725

Review 6.  The Identification, Review and Synthesis of Health State Utility Values from the Literature.

Authors:  Roberta Ara; John Brazier; Tessa Peasgood; Suzy Paisley
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 7.  Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Authors:  K Malottki; P Barton; A Tsourapas; A O Uthman; Z Liu; K Routh; M Connock; P Jobanputra; D Moore; A Fry-Smith; Y-F Chen
Journal:  Health Technol Assess       Date:  2011-03       Impact factor: 4.014

8.  The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.

Authors:  Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

Review 9.  Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database.

Authors:  Helen Dakin
Journal:  Health Qual Life Outcomes       Date:  2013-09-05       Impact factor: 3.186

10.  The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis.

Authors:  Mónica Hernández Alava; Allan Wailoo; Fred Wolfe; Kaleb Michaud
Journal:  Rheumatology (Oxford)       Date:  2013-01-21       Impact factor: 7.580

View more
  11 in total

1.  Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.

Authors:  Gang Chen; Miguel A Garcia-Gordillo; Daniel Collado-Mateo; Borja Del Pozo-Cruz; José C Adsuar; José Manuel Cordero-Ferrera; José María Abellán-Perpiñán; Fernando Ignacio Sánchez-Martínez
Journal:  Patient       Date:  2018-12       Impact factor: 3.883

Review 2.  A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement.

Authors:  Jihyung Hong; Eun-Young Bae
Journal:  Pharmacoeconomics       Date:  2021-07-28       Impact factor: 4.981

Review 3.  Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies.

Authors:  Roberta Ara; John Brazier; Tracey Young
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 4.  The Identification, Review and Synthesis of Health State Utility Values from the Literature.

Authors:  Roberta Ara; John Brazier; Tessa Peasgood; Suzy Paisley
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

5.  Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.

Authors:  Rahul Khairnar; Lyudmila DeMora; Howard M Sandler; W Robert Lee; Ester Villalonga-Olives; C Daniel Mullins; Francis B Palumbo; Deborah W Bruner; Fadia T Shaya; Soren M Bentzen; Amit B Shah; Shawn Malone; Jeff M Michalski; Ian S Dayes; Samantha A Seaward; Michele Albert; Adam D Currey; Thomas M Pisansky; Yuhchyau Chen; Eric M Horwitz; Albert S DeNittis; Felix Feng; Mark V Mishra
Journal:  JCO Clin Cancer Inform       Date:  2022-06

Review 6.  The Use of Health State Utility Values in Decision Models.

Authors:  Roberta Ara; John Brazier; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

7.  Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms.

Authors:  Michela Meregaglia; Rosanna Tarricone
Journal:  Pharmacoecon Open       Date:  2022-02-19

Review 8.  Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost-utility analyses.

Authors:  Jenny Rankin; Donna Rowen; Amanda Howe; John G F Cleland; Jennifer A Whitty
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

9.  Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis.

Authors:  Fan Yang; Carlos K H Wong; Nan Luo; James Piercy; Rebecca Moon; James Jackson
Journal:  Eur J Health Econ       Date:  2019-07-23

10.  Estimation of losses of quality-adjusted life expectancy attributed to the combination of cognitive impairment and multimorbidity among Chinese adults aged 45 years and older.

Authors:  Suting Xiong; Siyuan Liu; Yanan Qiao; Dingliu He; Chaofu Ke; Yueping Shen
Journal:  BMC Public Health       Date:  2021-01-05       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.